{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T23:33:50Z","timestamp":1787787230675,"version":"build-2784847793"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T00:00:00Z","timestamp":1776643200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:00:00Z","timestamp":1781222400000},"content-version":"vor","delay-in-days":53,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"DOI":"10.1038\/s41598-026-46923-x","type":"journal-article","created":{"date-parts":[[2026,4,20]],"date-time":"2026-04-20T17:18:38Z","timestamp":1776705518000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elevated plasma IgG is associated with improved treatment response and survival in advanced non\u2011small cell lung cancer patients treated with anti\u2011PD\u20111 therapy"],"prefix":"10.1038","volume":"16","author":[{"given":"Ryotaro","family":"Ohkuma","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nobuyuki","family":"Onishi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Makoto","family":"Watanabe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Jin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hirotsugu","family":"Ariizumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Shimokawa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Go","family":"Ikeda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoyuki","family":"Ishiguro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Risako","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toshiaki","family":"Tsurui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yutaro","family":"Kubota","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kiyoshi","family":"Yoshimura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shinichi","family":"Kobayashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takuya","family":"Tsunoda","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Horiike","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoshi","family":"Wada","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,20]]},"reference":[{"key":"46923_CR1","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.21.00174","volume":"39","author":"M Reck","year":"2021","unstructured":"Reck, M. et al. Five-year outcomes with pembrolizumab versus chemotherapy for metastatic non-small-cell lung cancer with PD-L1 tumor proportion score\u2009\u2265\u200950. J. Clin. Oncol. 39, 2339\u20132349. https:\/\/doi.org\/10.1200\/JCO.21.00174 (2021).","journal-title":"J. Clin. Oncol."},{"key":"46923_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1171649","volume":"14","author":"J Ancel","year":"2023","unstructured":"Ancel, J. et al. Soluble biomarkers to predict clinical outcomes in non-small cell lung cancer treated by immune checkpoints inhibitors. Front. Immunol. 14, 1171649. https:\/\/doi.org\/10.3389\/fimmu.2023.1171649 (2023).","journal-title":"Front. Immunol."},{"key":"46923_CR3","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0766-3","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: An analysis of all US Food and Drug Administration approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7, 278. https:\/\/doi.org\/10.1186\/s40425-019-0766-3 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"46923_CR4","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.964442","volume":"13","author":"Q Tang","year":"2022","unstructured":"Tang, Q. et al. The role of PD-1\/PD-L1 and application of immune-checkpoint inhibitors in human cancers. Front. Immunol. 13, 964442. https:\/\/doi.org\/10.3389\/fimmu.2022.964442 (2022).","journal-title":"Front. Immunol."},{"key":"46923_CR5","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2025.1614102","volume":"15","author":"M Watanabe","year":"2025","unstructured":"Watanabe, M. et al. Elevated plasma levels of WAP four-disulfide core domain 2 as a potential prognostic biomarker for various cancers. Front. Oncol. 15, 1614102. https:\/\/doi.org\/10.3389\/fonc.2025.1614102 (2025).","journal-title":"Front. Oncol."},{"key":"46923_CR6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17142384","volume":"17","author":"M Watanabe","year":"2025","unstructured":"Watanabe, M. et al. Plasma WFDC2 (HE4) as a predictive biomarker for clinical outcomes in cancer patients receiving anti-PD-1 therapy: A pilot study. Cancers (Basel) 17, 2384. https:\/\/doi.org\/10.3390\/cancers17142384 (2025).","journal-title":"Cancers (Basel)"},{"key":"46923_CR7","doi-asserted-by":"publisher","first-page":"23","DOI":"10.21873\/anticanres.16784","volume":"44","author":"T Goshima","year":"2024","unstructured":"Goshima, T. et al. Non-classical monocytes enhance the efficacy of immune checkpoint inhibitors on colon cancer in a syngeneic mouse model. Anticancer Res. 44, 23\u201329. https:\/\/doi.org\/10.21873\/anticanres.16784 (2024).","journal-title":"Anticancer Res."},{"key":"46923_CR8","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2023.1308381","volume":"14","author":"T Shimizu","year":"2023","unstructured":"Shimizu, T. et al. Soluble PD-L1 changes in advanced non-small cell lung cancer patients treated with PD-1 inhibitors: An individual patient data meta-analysis. Front. Immunol. 14, 1308381. https:\/\/doi.org\/10.3389\/fimmu.2023.1308381 (2023).","journal-title":"Front. Immunol."},{"key":"46923_CR9","doi-asserted-by":"publisher","DOI":"10.3892\/ol.2023.13967","volume":"26","author":"R Ohkuma","year":"2023","unstructured":"Ohkuma, R. et al. Monocyte subsets associated with the efficacy of anti-PD-1 antibody monotherapy. Oncol. Lett. 26, 381. https:\/\/doi.org\/10.3892\/ol.2023.13967 (2023).","journal-title":"Oncol. Lett."},{"key":"46923_CR10","doi-asserted-by":"publisher","DOI":"10.3390\/biomedicines9121929","volume":"9","author":"R Ohkuma","year":"2021","unstructured":"Ohkuma, R. et al. Increased plasma soluble PD-1 concentration correlates with disease progression in patients with cancer treated with anti-PD-1 antibodies. Biomedicines 9, 1929. https:\/\/doi.org\/10.3390\/biomedicines9121929 (2021).","journal-title":"Biomedicines"},{"key":"46923_CR11","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/MPA.0000000000001731","volume":"50","author":"R Ohkuma","year":"2021","unstructured":"Ohkuma, R. et al. The prognostic impact of eosinophils and the eosinophil-to-lymphocyte ratio on survival outcomes in stage II resectable pancreatic cancer. Pancreas 50, 167\u2013175. https:\/\/doi.org\/10.1097\/MPA.0000000000001731 (2021).","journal-title":"Pancreas"},{"key":"46923_CR12","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1007\/s00262-020-02672-4","volume":"70","author":"K Ando","year":"2021","unstructured":"Ando, K. et al. A high number of PD-L1\u2009+\u2009CD14+ monocytes in peripheral blood is correlated with shorter survival in patients receiving immune checkpoint inhibitors. Cancer Immunol. Immunother. 70, 337\u2013348. https:\/\/doi.org\/10.1007\/s00262-020-02672-4 (2021).","journal-title":"Cancer Immunol. Immunother."},{"key":"46923_CR13","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1097\/CJI.0000000000000255","volume":"42","author":"S Diem","year":"2019","unstructured":"Diem, S. et al. Immunoglobulin G and subclasses as potential biomarkers in metastatic melanoma patients starting checkpoint inhibitor treatment. J. Immunother. 42, 89\u201393. https:\/\/doi.org\/10.1097\/CJI.0000000000000255 (2019).","journal-title":"J. Immunother."},{"key":"46923_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41698-025-00891-z","volume":"9","author":"X Su","year":"2025","unstructured":"Su, X. et al. Tertiary lymphoid structures associated with improved survival and enhanced antitumor immunity in acral melanoma. NPJ Precis. Oncol. 9, 103. https:\/\/doi.org\/10.1038\/s41698-025-00891-z (2025).","journal-title":"NPJ Precis. Oncol."},{"key":"46923_CR15","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.ccell.2022.02.002","volume":"40","author":"NS Patil","year":"2022","unstructured":"Patil, N. S. et al. Intratumoral plasma cells predict outcomes to PD-L1 blockade in non-small cell lung cancer. Cancer Cell 40, 289-300.e4. https:\/\/doi.org\/10.1016\/j.ccell.2022.02.002 (2022).","journal-title":"Cancer Cell"},{"key":"46923_CR16","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0282680","volume":"18","author":"L Balcar","year":"2023","unstructured":"Balcar, L. et al. Early changes in immunoglobulin G levels during immune checkpoint inhibitor treatment are associated with survival in hepatocellular carcinoma patients. PLoS One 18, e0282680. https:\/\/doi.org\/10.1371\/journal.pone.0282680 (2023).","journal-title":"PLoS One"},{"key":"46923_CR17","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.euros.2024.10.004","volume":"70","author":"H Cui","year":"2024","unstructured":"Cui, H. et al. Dynamic changes in serum immunoglobulin G predict clinical response and prognosis in metastatic clear-cell renal cell carcinoma. Eur. Urol. Open Sci. 70, 109\u2013115. https:\/\/doi.org\/10.1016\/j.euros.2024.10.004 (2024).","journal-title":"Eur. Urol. Open Sci."},{"key":"46923_CR18","doi-asserted-by":"publisher","first-page":"558","DOI":"10.4097\/kja.19087","volume":"72","author":"JH Kim","year":"2019","unstructured":"Kim, J. H. Multicollinearity and misleading statistical results. Korean J. Anesthesiol. 72, 558\u2013569. https:\/\/doi.org\/10.4097\/kja.19087 (2019).","journal-title":"Korean J. Anesthesiol."},{"key":"46923_CR19","doi-asserted-by":"publisher","DOI":"10.4172\/2161-1165.1000227","volume":"6","author":"KP Vatcheva","year":"2016","unstructured":"Vatcheva, K. P., Lee, M., McCormick, J. B. & Rahbar, M. H. Multicollinearity in regression analyses conducted in epidemiologic studies. Epidemiology (Sunnyvale) 6, 227. https:\/\/doi.org\/10.4172\/2161-1165.1000227 (2016).","journal-title":"Epidemiology (Sunnyvale)"},{"key":"46923_CR20","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1093\/intimm\/dxs098","volume":"25","author":"ML Thibult","year":"2013","unstructured":"Thibult, M. L. et al. PD-1 is a novel regulator of human B-cell activation. Int. Immunol. 25, 129\u2013137. https:\/\/doi.org\/10.1093\/intimm\/dxs098 (2013).","journal-title":"Int. Immunol."},{"key":"46923_CR21","doi-asserted-by":"publisher","first-page":"2790","DOI":"10.1016\/j.immuni.2024.10.014","volume":"57","author":"M Ogishi","year":"2024","unstructured":"Ogishi, M. et al. Impaired development of memory B cells and antibody responses in humans and mice deficient in PD-1 signaling. Immunity 57, 2790-2807e.e15. https:\/\/doi.org\/10.1016\/j.immuni.2024.10.014 (2024).","journal-title":"Immunity"},{"key":"46923_CR22","first-page":"193","volume":"24","author":"O Dost\u00e1lov\u00e1","year":"1977","unstructured":"Dost\u00e1lov\u00e1, O., Wagnerov\u00e1, M., Sch\u00f6n, E., Wagner, V. & Jel\u00ednek, J. Serum immunoglobulin levels in cancer patients IV. The influence of therapy on the levels of IgG, IgA and IgM. Neoplasma 24, 193\u2013197 (1977).","journal-title":"Neoplasma"},{"key":"46923_CR23","doi-asserted-by":"publisher","first-page":"2536","DOI":"10.1111\/1759-7714.14573","volume":"13","author":"M Yasuda","year":"2022","unstructured":"Yasuda, M., Take, N., Shinohara, S. & Chikaishi, Y. Serum immunoglobulins might be useful predictors of immune-related adverse events after immune checkpoint inhibitor usage in lung cancer. Thorac. Cancer 13, 2536\u20132538. https:\/\/doi.org\/10.1111\/1759-7714.14573 (2022).","journal-title":"Thorac. Cancer"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46923-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46923-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46923-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T00:22:14Z","timestamp":1781223734000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-026-46923-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,20]]},"references-count":23,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["46923"],"URL":"https:\/\/doi.org\/10.1038\/s41598-026-46923-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,20]]},"assertion":[{"value":"5 February 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 March 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"This retrospective study was approved by the Ethics Committee of the Showa Medical University School of Medicine, Tokyo, Japan (approval numbers M2165 and M2253).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval"}},{"value":"Written informed consent for the participation and use of clinical data was obtained from all patients, and all data were anonymized in accordance with institutional and ethical guidelines.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}],"article-number":"18324"}}